Barry Maron to Survival Rate
This is a "connection" page, showing publications Barry Maron has written about Survival Rate.
Connection Strength
1.524
-
Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021 06; 18(6):1012-1023.
Score: 0.155
-
Rowin EJ, Maron MS, Wells S, Patel PP, Koethe BC, Maron BJ. Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2019 11 05; 8(21):e012041.
Score: 0.142
-
Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS. What Do Patients With Hypertrophic Cardiomyopathy Die from? Am J Cardiol. 2016 Feb 01; 117(3):434-5.
Score: 0.108
-
Link MS, Estes NAM, Maron BJ. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13: Commotio Cordis: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015 Dec 01; 66(21):2439-2443.
Score: 0.108
-
Sharkey SW, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ. Clinical Profile of Patients With High-Risk Tako-Tsubo Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):765-72.
Score: 0.105
-
Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):757-64.
Score: 0.105
-
Maron BJ, Haas TS, Murphy CJ, Ahluwalia A, Rutten-Ramos S. Incidence and causes of sudden death in U.S. college athletes. J Am Coll Cardiol. 2014 Apr 29; 63(16):1636-43.
Score: 0.096
-
Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013 Feb 05; 127(5):585-93.
Score: 0.088
-
Maron BJ, Casey SA, Haas TS, Kitner CL, Garberich RF, Lesser JR. Hypertrophic cardiomyopathy with longevity to 90 years or older. Am J Cardiol. 2012 May 01; 109(9):1341-7.
Score: 0.083
-
Maron BJ, Maron MS, Maron BA, Haas TS, Altman RK, Smalley SJ, Doerer JJ, Link MS, Mooney MR. Successful therapeutic hypothermia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011 Jun 14; 57(24):2454-6.
Score: 0.079
-
Link MS, Bir C, Dau N, Madias C, Estes NA, Maron BJ. Protecting our children from the consequences of chest blows on the playing field: a time for science over marketing. Pediatrics. 2008 Aug; 122(2):437-9.
Score: 0.065
-
Maron BJ. Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification. Cardiol Clin. 2007 Aug; 25(3):399-414, vi.
Score: 0.061
-
Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007 Jan 23; 49(3):350-7.
Score: 0.058
-
Aglan A, Fath AR, Maron BJ, Maron MS, Prasad A, Almomani A, Hammadah M, Reynolds MR, Rowin EJ. Percutaneous left atrial appendage closure for stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Heart Rhythm. 2024 09; 21(9):1677-1683.
Score: 0.049
-
Maron BJ, Piccininno M, Casey SA, Bernab? P, Spirito P. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am J Cardiol. 2003 Mar 01; 91(5):626-8.
Score: 0.045
-
Rowin EJ, Maron BJ, Romashko M, Wang W, Rastegar H, Link MS, Maron MS. Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy. Am J Cardiol. 2019 07 01; 124(1):113-121.
Score: 0.034
-
Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D. Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 04 15; 121(8):986-996.
Score: 0.031
-
Wang W, Lian Z, Rowin EJ, Maron BJ, Maron MS, Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017 Mar; 10(3).
Score: 0.030
-
Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, Maron MS. Hypertrophic Cardiomyopathy With Left?Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. J Am Coll Cardiol. 2017 02 21; 69(7):761-773.
Score: 0.029
-
Rowin EJ, Maron BJ, Appelbaum E, Link MS, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron MS. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol. 2012 Oct 01; 110(7):1027-32.
Score: 0.021
-
Hauser RG, Maron BJ, Marine JE, Lampert R, Kadish AH, Winters SL, Scher DL, Biria M, Kalia A. Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. Heart Rhythm. 2008 Nov; 5(11):1517-22.
Score: 0.016
-
Cha YM, Gersh BJ, Maron BJ, Boriani G, Spirito P, Hodge DO, Weivoda PL, Trusty JM, Friedman PA, Hammill SC, Rea RF, Shen WK. Electrophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2007 May; 18(5):483-7.
Score: 0.015